Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, The James Comprehensive Cancer Center, Columbus, OH 43210, USA.
Medicina (Kaunas). 2023 Jul 13;59(7):1290. doi: 10.3390/medicina59071290.
Transplant oncology is a relatively new field in which transplantation is used to treat patients who would otherwise be unresectable. New anticancer treatment paradigms using tumor and transplant immunology and cancer immunogenomics are emerging. In turn, liver transplantation (LT) has become a potential therapy for certain patients with colorectal cancer (CRC) with liver metastasis, hepatocellular (HCC), cholangiocarcinoma (CCA), and metastatic neuroendocrine tumor (NET) of the liver. Although there are established criteria for LT in HCC, evidence regarding LT as a treatment modality for certain gastrointestinal malignancies is still debated. The aim of this review is to highlight updates in the role of LT for certain malignancies, including HCC, metastatic CRC, hilar CCA, and neuroendocrine tumor (NET), as well as contextualize LT use and discuss controversies in transplant oncology.
移植肿瘤学是一个相对较新的领域，其中移植被用于治疗否则无法切除的患者。使用肿瘤和移植免疫学和癌症免疫基因组学的新抗癌治疗范例正在出现。反过来，肝移植 (LT) 已成为某些患有结直肠癌 (CRC) 肝转移、肝细胞癌 (HCC)、胆管细胞癌 (CCA) 和肝转移性神经内分泌肿瘤 (NET) 的患者的潜在治疗方法。尽管 HCC 有 LT 的既定标准，但关于 LT 作为某些胃肠道恶性肿瘤治疗方式的证据仍存在争议。本综述的目的是强调 LT 在某些恶性肿瘤中的作用的最新进展，包括 HCC、转移性 CRC、肝门部 CCA 和神经内分泌肿瘤 (NET)，并将 LT 的使用置于上下文中，并讨论移植肿瘤学中的争议。
